Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10334547rdf:typepubmed:Citationlld:pubmed
pubmed-article:10334547lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0332441lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0135096lld:lifeskim
pubmed-article:10334547lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:10334547pubmed:issue5lld:pubmed
pubmed-article:10334547pubmed:dateCreated1999-5-27lld:pubmed
pubmed-article:10334547pubmed:abstractTextTo evaluate the effect of N-phosphonacetyl-L-aspartate (PALA), folinic acid (FA), and interferon alfa (IFN-alpha) biomodulation on plasma fluorouracil (5FU) pharmacokinetics and tumor and liver radioactivity uptake and retention after [18F]-fluorouracil (5-[18F]-FU) administration.lld:pubmed
pubmed-article:10334547pubmed:languageenglld:pubmed
pubmed-article:10334547pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:citationSubsetIMlld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10334547pubmed:statusMEDLINElld:pubmed
pubmed-article:10334547pubmed:monthMaylld:pubmed
pubmed-article:10334547pubmed:issn0732-183Xlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:MatthewsJ CJClld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:BrownGGlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:JonesTTlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:OsmanSSlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:BradyFFlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:PriceP MPMlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:O'ReillyS MSMlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:TilsleyD WDWlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:HarteR JRJlld:pubmed
pubmed-article:10334547pubmed:authorpubmed-author:LuthraS JSJlld:pubmed
pubmed-article:10334547pubmed:issnTypePrintlld:pubmed
pubmed-article:10334547pubmed:volume17lld:pubmed
pubmed-article:10334547pubmed:ownerNLMlld:pubmed
pubmed-article:10334547pubmed:authorsCompleteYlld:pubmed
pubmed-article:10334547pubmed:pagination1580-8lld:pubmed
pubmed-article:10334547pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:meshHeadingpubmed-meshheading:10334547...lld:pubmed
pubmed-article:10334547pubmed:year1999lld:pubmed
pubmed-article:10334547pubmed:articleTitleTumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.lld:pubmed
pubmed-article:10334547pubmed:affiliationMedical Research Council, Cancer Research Campaign Positron Emission Tomography Research Group, Imperial College School of Medicine, London, United Kingdom.lld:pubmed
pubmed-article:10334547pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10334547pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10334547lld:pubmed